eGenesis
Financing Round
- Series C
Round Led by Symbiosis
eGenesis’s goal is to transform the field of transplantation by offering safe and effective organs, tissues, and cells to patients in need. The company harnesses cutting-edge gene editing technologies to address the key issues that have impeded xenotransplantation to date. eGenesis’s development pipeline includes lead programs for kidney and islet cell transplant as well as earlier-stage programs focused on other solid organs.
View Website
Modality
- Genetic Medicine
Indications
- Immunology & Inflammation
- Other
Development Status
- Phase 1